Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2122 |
Ixazomib
艾沙佐米,MLN2238 |
Proteasome; Caspase; Autophagy | Apoptosis; Autophagy; Proteases/Proteasome; Ubiquitination |
Ixazomib (MLN2238) 含硼肽蛋白酶体抑制剂(PI),可抑制 20S 蛋白酶体的糜蛋白酶样蛋白水解 (β5) 位点,IC50为 3.4 nM,Ki 为 0.93 nM。它还抑制半胱天冬酶样 (β1) 和胰蛋白酶样 (β2) 蛋白水解位点,IC50值为 31和3500 nM。 | |||
T69983 |
Ixazomib citrate EtOH
|
||
Ixazomib citrate, also known as MLN9708, is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN9708, compared with bortezomib, has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinic... | |||
T8397 |
Ixazomib citrate
枸橼酸艾沙佐米,MLN9708 |
Proteasome; Autophagy | Autophagy; Proteases/Proteasome; Ubiquitination |
Ixazomib citrate (MLN9708) 是 Ixazomib 的前药,是20S 蛋白酶体胰凝乳蛋白酶样蛋白水解β5位点的可逆抑制剂,IC50为3.4 nM 和Ki 为0.93 nM。 |